Log in to search using one of your social media accounts:

 

Blood-thinning drugs may reduce dementia risk in people with irregular heartbeats
Conclusion If you’ve been diagnosed with AF and you have been prescribed anticoagulant treatments such as warfarin or clopidogrel, we already know they protect you against having a stroke. This study suggests they may also help to protect you against dementia. Cutting the risk of dementia for people who have a raised risk because of AF would be an exciting step forward. Unfortunately, we can’t tell from this study whether the protection against dementia was down to the anticoagulants, because of the possible effect of unmeasured confounding factors. Usually, we would want to see a randomised controlled trial (R...
Source: NHS News Feed - October 25, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

You won ’t believe what happened this morning
When I got to the office this morning, several of my employees were in a state of near-panic… I couldn’t imagine what might have happened… and I was alarmed. Turns out, the coffee maker was on the fritz. Coffee is the “drug” of choice for many of the people on my staff. And they’re not alone… An astounding 80% of Americans use the caffeine in coffee to boost their energy. The buzz helps them wake up every morning and gets their day going. And older adults drink coffee more than anyone else. In fact, in a survey by the National Coffee Association, 20% of people over 64 said they ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Judge: Firms must have permanent, physical presence in Delaware to file patent suits there
The District of Delaware Chief Judge said this week that businesses must have permanent residences in the state to be sued for patent infringement within it, following a series of US Supreme Court rulings, and transferred a patent spat case to Indiana. Chief Judge Leonard Stark said the precedent was set after the Supreme Court’s decision in TC Heartland LLC v. Kraft Food Group Brands and Bristol-Myers Squibb Co. v. Superior Court of California earlier this year. In TC Heartland v. Kraft Foods Group Brands, the Supremes limited the ability of patent holders to sue in other states. Kraft sued TC Heartland in...
Source: Mass Device - September 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Boston Scientific Cook Medical Source Type: news

Platelet Testing Guides Prasugrel-to-Clopidogrel Switch Post-ACS Platelet Testing Guides Prasugrel-to-Clopidogrel Switch Post-ACS
The TROPICAL-ACS trial has validated a new"deescalation" regimen of antiplatelet therapy that could be applicable to patients unsuitable for long-term potent therapy due to bleeding or affordability concerns.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Ticagrelor for DAPT Again Questioned in Modern-Era PCI for ACS Ticagrelor for DAPT Again Questioned in Modern-Era PCI for ACS
More bleeds than clopidogrel without a clinical upside: Maybe ticagrelor isn't the best for dual antiplatelet therapy in PCI for ACS, given the prowess of modern drug-eluting stents, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

ESC: Ticagrelor Fails to Improve on Clopidogrel After Switch
(MedPage Today) -- Single-center study contradicts PLATO in ACS patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2017 Category: Cardiology Source Type: news

FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug
[03-12-2010] The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Plavix, the anti-blood clotting medication. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

Late Stent Events Linked to Response to Clopidogrel, Not ASA
(MedPage Today) -- Longer-term trial data suggests limited value to platelet reactivity testing (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 3, 2017 Category: Cardiology Source Type: news

Medical device makers look to slip lawsuits on Supreme Court ruling
A trio of medical device makers are looking to slip patent infringement and product liability lawsuits based on recent U.S. Supreme Court rulings governing out-of-state lawsuits. In TC Heartland v. Kraft Foods Group Brands, the Supremes limited the ability of patent holders to sue in other states. Kraft sued TC Heartland in its incorporated state of Delaware over drink powder patents; a lower court blocked TC Heartland’s bid to move the case to its home base of Indiana. In May, the Supreme court reversed that decision, finding that the only place a defendant can be subject to a suit is their home court, a p...
Source: Mass Device - July 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Legal News Patent Infringement Abbott Boston Scientific Ethicon johnsonandjohnson Personal Injury stjudemedical Source Type: news

Supremes tighten the rules on out-of-state lawsuits
The Supreme Court this week put limits on where injuries lawsuits can be fired, siding with businesses to prevent plaintiffs from “shopping” for friendly courts. The justices overturned a lower court’s decision that had allowed out-of-state patients who took Bristol-Myers Squibb’s Plavix blood-thinning medication to file a suit against the company in California. Under the justice’s ruling, state courts cannot hear claims against companies that are not based in the state where the injuries occurred. The Supreme Court arrived at a similar conclusion in a separate case in May 30. Businesses can t...
Source: Mass Device - June 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Source Type: news

Prasugrel Fails to Show Noninferiority to Clopidogrel in Stroke Prasugrel Fails to Show Noninferiority to Clopidogrel in Stroke
Despite being a more potent antiplatelet agent, prasugrel failed to show noninferiority to clopidogrel in reducing vascular events in stroke patients in a new phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

In ACS, Less Bleeding With Two-Step Post-PCI DAPT Strategy In ACS, Less Bleeding With Two-Step Post-PCI DAPT Strategy
Switching to clopidogrel after 1 month of prasugrel or ticagrelor reduces bleeding without increasing ischemic events in the open-label, single-center TOPIC study.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

DAPT Safer With Switch from P2Y12 Blockers Early After Stenting (CME/CE)
(MedPage Today) -- Substituting in clopidogrel after a month cuts bleeding risk, trial says (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 16, 2017 Category: Cardiology Source Type: news

Ischemic Outcomes Don ’ t Vary With Gender in ACS Patients
No difference by gender for ACS patients undergoing PCI receiving clopidogrel, prasugrel, or ticagrelor (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 4, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Plavix (Clopidogrel Bisulfate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 28, 2017 Category: Drugs & Pharmacology Source Type: news

Platelet Function Testing Important With Pipeline Embolization Platelet Function Testing Important With Pipeline Embolization
Identification of patients who will be poor responders to antiplatelet therapy with clopidogrel can help avoid thromboembolic complications after flow diversion procedures for intracranial aneurysm.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Major Bleeding Risk From Drugs Similar in Elderly
Elderly taking aspirin, clopidogrel have major bleeding similar to that seen with oral anticoagulants (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 17, 2017 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Geriatrics, Internal Medicine, Neurology, Nursing, Oncology, Pharmacy, Journal, Source Type: news

Are Blood Thinners Overused in Patients With Irregular Heartbeat?
FRIDAY, March 17, 2017 -- Many people living with the heart rhythm disorder known as atrial fibrillation may be taking unneeded blood thinners, a new study suggests. These blood thinners, which include aspirin, Plavix and warfarin, are believed to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 17, 2017 Category: Journals (General) Source Type: news

TARDIS: Triple Antiplatelet Therapy No Benefit in Stroke, TIA TARDIS: Triple Antiplatelet Therapy No Benefit in Stroke, TIA
Triple antiplatelet therapy was not superior to guideline-recommended aspirin/dipyridamole or clopidogrel alone to prevent recurrent stroke in patients with recent stroke or TIA in the TARDIS trial.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 24, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Ticagrelor More Effective Than Clopidogrel in Some Cardiac Arrest Survivors Ticagrelor More Effective Than Clopidogrel in Some Cardiac Arrest Survivors
In comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention (PCI) and hypothermia, ticagrelor results in faster and stronger platelet inhibition compared to clopidogrel, researchers in Slovenia say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 30, 2016 Category: Consumer Health News Tags: News Source Type: news

Kengreal Sans GPI Safe in PCI, With Less Bleeding (CME/CE)
(MedPage Today) -- Only TIMI bleeds differed from Plavix-GPI combo in meta-analysis (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 1, 2016 Category: Cardiology Source Type: news

Cangrelor Sans GPI Safe in PCI, With Less Bleeding (CME/CE)
(MedPage Today) -- Only TIMI bleeds differed from Plavix-GPI combo in meta-analysis (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 1, 2016 Category: Cardiology Source Type: news

Breaking News from AHA 2016: Genetic Risk & Healthy Lifestyle, Ticagrelor vs. Clopidogrel in PAD, Targeting PCSK9 (FREE)
By the Editors This week, NEJM Journal Watch is bringing you coverage of breaking news from the American Heart Association's Scientific Sessions in New Orleans. Take a look:Genetic Risk and Healthy Lifestyle: A healthy lifestyle can mitigate high genetic risk for coronary artery disease, according to an analysis of data … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 13, 2016 Category: Primary Care Source Type: news

EUCLID: Ticagrelor, Clopidogrel in PAD Similar for CV Events EUCLID: Ticagrelor, Clopidogrel in PAD Similar for CV Events
Those getting ticagrelor had fewer ischemic strokes, but that was only a part of the primary end point. It might have been related to the drug's effects on blood pressure, says an expert.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

AHA: More Potent Antiplatelet Agent Not Better for PAD (CME/CE)
(MedPage Today) -- Ticagrelor no better than clopidogrel in EUCLID trial (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 13, 2016 Category: Geriatrics Source Type: news

CardioBrief: Ticagrelor No Better Than Clopidogrel in PAD
(MedPage Today) -- Top-line results from EUCLID trial announced ahead of AHA meeting (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 4, 2016 Category: Cardiology Source Type: news

Why 5,000 People Are Suing Over Plavix
Legal action is apparently moving forward involving lawsuits filed by thousands of people who say they suffered serious injuries by taking the once-heralded blood-thinning drug Plavix. The California Supreme Court ruled late last month that eight product liability lawsuits against Plavix manufacturer Bristol-Myers Squibb and Plavix distributor McKesson Corporation can proceed in San Francisco Superior Court. Those eight cases involved 678 plaintiffs. They may soon be joined by a multitude of other cases, involving about 5,000 plaintiffs, that have been filed around the country. There is no word yet on whether Bristol-My...
Source: Healthy Living - The Huffington Post - September 13, 2016 Category: Consumer Health News Source Type: news

Serious Infection With STEMI PCI May Hurt Angiographic Results Serious Infection With STEMI PCI May Hurt Angiographic Results
More potent antiplatelets"such as ticagrelor instead of clopidogrel in patients with ACS and serious infections could be of benefit," the authors suggest.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Plavix Smoker's Paradox Debunked? (CME/CE)
(MedPage Today) -- Hemoglobin confounds platelet level readings, study suggests (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 16, 2016 Category: Geriatrics Source Type: news

Real-world data confirm benefits of ticagrelor in ACS
A prospective study of more than 45,000 patients with acute coronary syndromes has shown that the risk of death or readmission with myocardial infarction or stroke is 15% lower with ticagrelor than with clopidogrel. (Source: MedWire News)
Source: MedWire News - July 26, 2016 Category: Consumer Health News Tags: Acute coronary syndromes Source Type: news

Plavix vs Effient: No Consistent Winner In Real-World Data (CME/CE)
(MedPage Today) -- Separate analyses yield conflicting results on the same observational data (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 20, 2016 Category: Geriatrics Source Type: news

Genetic Testing to Guide Clopidogrel Treatment in Stroke/TIA?Genetic Testing to Guide Clopidogrel Treatment in Stroke/TIA?
A substudy of the CHANCE trial shows clopidogrel is of no additional benefit over aspirin alone for patients with TIA or minor stroke who carry the clopidogrel loss-of-function genes. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 5, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

As preventive, H2RA poses risks for patients on clopidogrel after bleeding ulcer
SAN DIEGO – New research suggests histamine-2 receptor antagonists aren’t a viable alternative to proton pump inhibitors to prevent recurrence of bleeding peptic ulcers in clopidogrel users. U.S.... (Source: Family Practice News)
Source: Family Practice News - June 27, 2016 Category: Primary Care Source Type: news

Gene Variant Reduces Plavix Response After Minor Stroke (CME/CE)
(MedPage Today) -- GYP2C19 genotyping may identify nonresponsive patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 27, 2016 Category: Cardiology Source Type: news

Gene Variant Reduces Clopidogrel Response After Minor Stroke (CME/CE)
(MedPage Today) -- CYP2C19 genotyping may identify nonresponsive patients (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - June 26, 2016 Category: Neurology Source Type: news

CYP2C19 gene variants undermine clopidogrel stroke prevention
The first look at CYP2C19 mutations in the context of a randomised controlled trial has confirmed suspicions that they affect the efficacy of clopidogrel in patients with acute stroke. (Source: MedWire News)
Source: MedWire News - June 24, 2016 Category: Consumer Health News Tags: Stroke Source Type: news

Clopidogrel and Hip Fractures, Is It Safe?Clopidogrel and Hip Fractures, Is It Safe?
The perioperative management of patients on anticoagulant or antiplatelet therapy can be challenging, and orthopedic surgeons must weigh the risks and benefits. Find out what there is to know. BMC Musculoskeletal Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2016 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news

Better than Aspirin for Your Heart
If you’ve been diagnosed with heart disease, the chances are you’ve been told to take low-dose aspirin every day as a preventative measure against heart attack and stroke. It’s most commonly prescribed for patients with congestive heart failure. This is the inability of your heart to pump as much blood as your body needs. And this is a big worry to me, because there is very little evidence that aspirin helps. In fact, regular use of aspirin — even baby aspirin — can do you more harm than good. Common Aspirin Beliefs The idea is that aspirin thins the blood, making it easier to pump.  It i...
Source: Al Sears, MD Natural Remedies - April 1, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news

Brilinta preferred over clopidogrel in updated American College of Cardiology and American Heart Association guideline in acute coronary syndrome
AstraZeneca today confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual antiplatelet therapy (DAPT). Brilinta (ticagrelor) is now preferred over clopidogrel for the management of patients with acute coronary syndrome (ACS) who have received a coronary stent and in non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) patients treated with medical therapy alone (Class IIa LoE: B-R). (Source: World Pharma News)
Source: World Pharma News - March 31, 2016 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug
[03-12-2010] The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Plavix, the anti-blood clotting medication. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 24, 2016 Category: Drugs & Pharmacology Source Type: news

FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole
The U.S. Food and Drug Administration (FDA) is reminding the public that it continues to warn against the concomitant use of Plavix (clopidogrel) and omeprazole because the co-administration can result in significant reductions in clopidogrel's active metabolite levels and antiplatelet activity. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2016 Category: Drugs & Pharmacology Source Type: news

ISC: Newer Anticoagulants Riskier for Afib Patients Needing Antiplatelet Tx? (CME/CE)
(MedPage Today) -- More bleeds versus warfarin in combination with clopidogrel post-PCI (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2016 Category: Cardiology Source Type: news

Brilinta Beats Plavix in Onset of Action Post-PCI (CME/CE)
(MedPage Today) -- Pharmacodynamic study suggests advantage for ticagrelor (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 9, 2016 Category: Cardiology Source Type: news

Long-Term Plavix Tx Linked to ACS Risk
(MedPage Today) -- Stent thrombosis, other adverse outcomes more common with chronic treatment (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 31, 2016 Category: Cardiology Source Type: news

Genetics Home Reference: clopidogrel resistance
http://ghr.nlm.nih.gov/condition/clopidogrel-resistance (Source: NLM General Announcements)
Source: NLM General Announcements - December 29, 2015 Category: Databases & Libraries Source Type: news

Similar Low Cancer Rates With Two DAPT Strategies in TRILOGY ACSSimilar Low Cancer Rates With Two DAPT Strategies in TRILOGY ACS
New cancers occurred infrequently in patients with unstable angina or MI, and the rates were comparable in those taking dual antiplatelet therapy with aspirin plus prasugrel or clopidogrel. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 18, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

How Your Genes Influence What Medicines Are Right for You
This article was originally published on The Conversation. Read the original article. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - November 22, 2015 Category: Consumer Health News Source Type: news

CANOA: Clopidogrel Reduces Migraine After ASD ClosureCANOA: Clopidogrel Reduces Migraine After ASD Closure
The study provides definitive data that dual antiplatelet therapy leads to fewer migraines after transcatheter closure of an atrial septal defect, the lead author says. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

FDA: Long-Term Clopidogrel Doesn't Affect Mortality Rates in Heart Patients (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Long-term treatment with clopidogrel (Plavix) doesn't increase or decrease the overall risk for death in patients with, or at risk for, heart disease, according to the results of an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 8, 2015 Category: Primary Care Source Type: news

FDA: No Long-Term Clopidogrel Mortality, Cancer Risks FDA: No Long-Term Clopidogrel Mortality, Cancer Risks
In today's MedWatch, the agency reports results from its meta-analyses, which included a review of DAPT and other large clinical trials that examined adverse events from clopidogrel use. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 7, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news